Awardee OrganizationUNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
Description
Abstract Text
The Acquired Immune Deficiency Syndrome (AIDS) results from infection with
the human immunodeficiency virus (HIV-1). AIDS is characterized by
profound and/or neoplasms in the infected individual. In addition to
deficiencies in T mononuclear cells from AIDS patients to make interferon-
alpha in response to herpes simplex virus type-1 infected fibroblasts has
been observed. This deficiency was strongly correlated with the presence
of OI in the patients studied and was also predictive of OI in the follow-
up period for those not yet meeting the AIDS case definition. The cells
responsible for IFN-alpha production were found to be light density HLA-DR
positive cells and shared the phenotype of peripheral blood dendritic
cells. In the present application, studies will be undertaken to
positively identify the IFN-alpha producing cells, determine the
interaction of HIV with this population and determine the mechanism of
deficient IFN-alpha production in patients with AIDS and OI. Because the
DR-positive cells represent only a small fraction of the mononuclear cells,
density gradient techniques and sequential depletions with monoclonal
antibodies will be utilized for enrichment. Frequency of IFN-producing
cells will be monitored by immunoplaque assay and IFN-gene expression in
activated cells will be measured by S1 mapping. Immunocytochemical and
immuno-gold techniques for electron microscopy using antibodies to IFN will
allow for direct detection of morphology of IFN-alpha producing cells.
Enriched IFN-alpha producing cells will be used to determine the effect of
HIV on these populations. Whether HIV replicates in and/or kills these
cells will be determined and the effect of HIV on functional assays will be
investigated. Finally, an evaluation of the mechanism of deficiency of
IFN-alpha production in AIDS patients will be undertaken. IFN-alpha
producing cells from AIDS patients will be evaluated using techniques
developed in this application and functional studies involving co-culture
to look for possible suppressor cells or factors will be performed.
Together, the proposed experiments involving both basic biology and patient
studies should provide important information regarding an important
mechanism of AIDS pathogenesis.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AIDSMHC class II antigendensity gradient ultracentrifugationfibroblastsgene expressiongenetic transcriptionhelper T lymphocytehuman immunodeficiency virus 1human subjecthuman tissueimmunocytochemistryimmunoelectron microscopyin situ hybridizationinterferonslaboratory mousemixed lymphocyte reaction testmonoclonal antibodyopportunistic infectionspathologic processpolymerase chain reactionprotein biosynthesistissue /cell culture
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
623946217
UEI
Project Start Date
15-June-1991
Project End Date
31-May-1994
Budget Start Date
01-June-1992
Budget End Date
31-May-1993
Project Funding Information for 1992
Total Funding
$158,784
Direct Costs
$98,015
Indirect Costs
$60,769
Year
Funding IC
FY Total Cost by IC
1992
National Institute of Allergy and Infectious Diseases
$158,784
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI026806-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI026806-02
Patents
No Patents information available for 5R01AI026806-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI026806-02
Clinical Studies
No Clinical Studies information available for 5R01AI026806-02
News and More
Related News Releases
No news release information available for 5R01AI026806-02
History
No Historical information available for 5R01AI026806-02
Similar Projects
No Similar Projects information available for 5R01AI026806-02